Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3078-3084

  Pinna, Debora ^a   Oreste, Pasqua ^b   Coradin, Tiziana ^a   Kajaste Rudnitski, Anna ^a   Ghezzi, Silvia ^a   Zoppetti, Giorgio ^b   Rotola, Antonella ^d   Argnani, Rafaela ^d   Poli, Guido ^a,c   Manservigi, Roberto ^d   Vicenzi, Elisa ^a,e  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c Institute of Psychology   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e P2 P3 Laboratories   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BACTERIAL POLYSACCHARIDE; K5 POLYSACCHARIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; ESCHERICHIA COLI; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; NONHUMAN; PRIORITY JOURNAL; VERO CELL; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; BACTERIAL CAPSULES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; EPITHELIAL CELLS; ESCHERICHIA COLI; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; RECOMBINATION, GENETIC; SULFATES; VERO CELLS;

EID: 50949128548     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00359-08     Document Type: Article

References (40)

1. Balzarini, J., and L. Van Damme. 2007. Microbicide drug candidates to prevent HIV infection. Lancet 369:787-797.
2. Bender, F. C., J. C. Whitbeck, H. Lou, G. H. Cohen, and R. J. Eisenberg. 2005. Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry. J. Virol. 79:11588-11597.
3. Carr, D. J., and L. Tomanek. 2006. Herpes simplex virus and the chemokines that mediate the inflammation. Curr. Top. Microbiol. Immunol. 303:47-65.
4. Casu, B., G. Grazioli, N. Razi, M. Guerrini, A. Naggi, G. Torri, P. Oreste, F. Tursi, G. Zoppetti, and U. Lindahl. 1994. Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr. Res. 263:271-284.
5. Casu, B., M. Petitou, M. Provasoli, and P. Sinay. 1988. Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem. Sci. 13:221-225.
6. Cheshenko, N., and B. C. Herold. 2002. Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread. J. Gen. Virol. 83:2247-2255.
7. Cheshenko, N., M. J. Keller, V. MasCasullo, G. A. Jarvis, H. Cheng, M. John, J. H. Li, K. Hogarty, R. A. Anderson, D. P. Waller, L. J. Zaneveld, A. T. Profy, M. E. Klotman, and B. C. Herold. 2004. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob. Agents Chemother. 48:2025-2036.
8. Corey, L. 2002. Challenges in genital herpes simplex virus management. J. Infect. Dis. 186(Suppl. 1):S29-S33.
9. Corey, L., A. Wald, C. L. Celum, and T. C. Quinn. 2004. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J. Acquir. Immune Defic. Syndr. 35:435-445.
10. Duff, R., and F. Rapp. 1971. Properties of hamster embryo fibroblasts transformed in vitro after exposure to ultraviolet-irradiated herpes simplex virus type 2. J. Virol. 8:469-477.
11. Esmann, J. 2001. The many challenges of facial herpes simplex virus infection. J. Antimicrob. Chemother. 47(Suppl. T1):17-27.
12. Eustice, D. C., P. A. Feldman, A. M. Colberg-Poley, R. M. Buckery, and R. H. Neubauer. 1991. A sensitive method for the detection of beta-galactosidase in transfected mammalian cells. BioTechniques 11:739-743.
13. Fleming, D. T., G. M. McQuillan, R. E. Johnson, A. J. Nahmias, S. O. Aral, F. K. Lee, and M. E. St. Louis. 1997. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337:1105-1111.
14. Freeman, E. E., H. A. Weiss, J. R. Glynn, P. L. Cross, J. A. Whitworth, and R. J. Hayes. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73-83.
15. Goldstein, D. J., and S. K. Weller. 1988. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62:196-205.
16. Gupta, R., T. Warren, and A. Wald. 2007. Genital herpes. Lancet 370:2127-2137.
17. Hagner-McWhirter, A., U. Lindahl, and J. Li. 2000. Biosynthesis of heparin/ heparan sulphate: mechanism of epimerization of glucuronyl C-5. Biochem. J. 347:69-75.
18. Hricovini, M., M. Guerrini, G. Torri, and B. Casu. 1997. Motional properties of E. coli polysaccharide K5 in aqueous solution analyzed by NMR relaxation measurements. Carbohydr. Res. 300:69-76.
19. Jones, L. S., B. Yazzie, and C. R. Middaugh. 2004. Polyanions and the protcomc. Mol. Cell. Proteomics 3:746-769.
20. Keller, M. J., A. Tuyama, M. J. Carlucci, and B. C. Herold. 2005. Topical microbicides for the prevention of genital herpes infection. J. Antimicrob. Chemother. 55:420-423.
21. Keller, M. J., B. Zerhouni-Layachi, N. Cheshenko, M. John, K. Hogarty, A. Kasowitz, C. L. Goldberg, S. Wallenstein, A. T. Profy, M. E. Klotman, and B. C. Herold. 2006. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J. Infect. Dis. 193:27-35.
22. Labrosse, B., A. Brelot, N. Heveker, N. Sol, D. Schols, E. De Clercq, and M. Alizon. 1998. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J. Virol. 72:6381-6388.
23. Laquerre, S., R. Argnani, D. B. Anderson, S. Zucchini, R. Manservigi, and J. C. Glorioso. 1998. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J. Virol. 72:6119-6130.
24. Lembo, D., M. Donalisio, M. Rusnati, A. Bugatti, M. Cornaglia, P. Cappello, M. Giovarelli, P. Oreste, and S. Landolfo. 2008. Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus. Antimicrob. Agents Chemother. 52:1374-1381.
25. Lindahl, U., J. P. Li, M. Kusche-Gullberg, M. Salmivirta, S. Alaranta, T. Veromaa, J. Emeis, I. Roberts, C. Taylor, P. Oreste, G. Zoppetti, A. Naggi, G. Torri, and B. Casu. 2005. Generation of "neoheparin" from E. coli K5 capsular polysaccharide. J. Med. Chem. 48:349-352.
26. Looker, K. J., and G. P. Garnett. 2005. A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex. Transm Infect. 81:103-107.
27. Lycke, E., M. Johansson, B. Svennerholm, and U. Lindahl. 1991. Binding of herpes simplex virus to cellular heparan sulphate, an initial step in the adsorption process. J. Gen. Virol. 72:1131-1137.
28. Madan, R. P., P. M. Mesquita, N. Cheshenko, B. Jing, V. Shende, E. Guzman, T. Heald, M. J. Keller, S. L. Regen, R. J. Shattock, and B. C. Herold. 2007. Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J. Virol. 81:7636-7646.
29. Nyberg, K., M. Ekblad, T. Bergstrom, C. Freeman, C. R. Parish, V. Ferro, and E. Trybala. 2004. The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus. Antivir. Res. 63: 15-24.
30. Oyan, A. M., K. E. Dolter, N. Langeland, W. F. Goins, J. C. Glorioso, L. Haarr, and C. S. Crumpacker. 1993. Resistance of herpes simplex virus type 2 to neomycin maps to the N-terminal portion of glycoprotein C. J. Virol. 67:2434-2441.
31. Raman, R., G. Venkataraman, S. Ernst, V. Sasisekharan, and R. Sasisekharan. 2003. Structural specificity of heparin binding in the fibroblast growth factor family of proteins. Proc. Natl. Acad. Sci. USA 100:2357-2362.
32. Razi, N., E. Feyzi, I. Bjork, A. Naggi, B. Casu, and U. Lindahl. 1995. Structural and functional properties of heparin analogues obtained by chemical sulphation of Escherichia coli K5 capsular polysaccharide. Biochem. J. 309:465-472.
33. Sato, H., J. Orenstein, D. Dimitrov, and M. Martin. 1992. Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. Virology 186:712-724.
34. Trybala, E., J. A. Liljeqvist, B. Svennerholm, and T. Bergstrom. 2000. Herpes simplex virus types 1 and 2 differ in their interaction with heparan sulfate. J. Virol. 74:9106-9114.
35. Vann, W. F., M. A. Schmidt, B. Jann, and K. Jann. 1981. The structure of the capsular polysaccharide (K5 antigen) of urinary-tract-infective Escherichia coli 010:K5:H4. A polymer similar to desulfo-heparin. Eur. J. Biochem. 116:359-364.
36. Vicenzi, E., A. Gatti, S. Ghezzi, P. Oreste, G. Zoppetti, and G. Poli. 2003. Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives. AIDS 17:177-181.
37. Wald, A., J. Zeh, S. Selke, R. L. Ashley, and L. Corey. 1995. Virologic characteristics of subclinical and symptomatic genital herpes infections. N. Engl. J. Med. 333:770-775.
38. Whitley, R. J., and B. Roizman. 2001. Herpes simplex virus infections. Lancet 357:1513-1518.
39. WuDunn, D., and P. G. Spear. 1989. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J. Virol. 63:52-58.
40. Zaneveld, L. J., D. P. Waller, R. A. Anderson, C. Chany II, W. F. Rencher, K. Feathergill, X. H. Diao, G. F. Doncel, B. Herold, and M. Cooper. 2002. Efficacy and safety of a new vaginal contraceptive antimicrobial formulation containing high molecular weight poly(sodium 4-styrenesulfonate). Biol. Reprod. 66:886-894.